RedHill Biopharma Ltd. (RDHL) Monday said the Food and Drug Administration or FDA has granted orphan-drug designation to its opaganib for the treatment of neuroblastoma, a type of childhood cancer.
Orphan Drug designation provides for a seven-year marketing exclusivity after the drug's approval, and other benefits including research grants, tax credits etc.
This is the second orphan drug designation by the FDA for opaganib in oncology, after cholangiocarcinoma or bile duct cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.